Rhena Ruiz-Novero, MD
Family Medicine · Naples, FLNPI 1235144932
Payments from drug & device makers
Across 293 payments — averaging $36.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Novo Nordisk$974
- GSK$591
- plus $3K from 26 others
What the payments were for
- Food & beverage$10,577100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 49 | $1,719 |
| Johnson & Johnson | 24 | $1,546 |
| AstraZeneca | 35 | $1,440 |
| Boehringer Ingelheim | 41 | $1,237 |
| Novo Nordisk | 27 | $974 |
| GSK | 18 | $591 |
| Amarin Pharma, Inc. | 11 | $495 |
| Lilly USA, LLC | 21 | $455 |
| Pfizer | 16 | $376 |
| Boston Scientific | 3 | $294 |
| Merck | 6 | $189 |
| Novartis | 5 | $175 |
| Abbott | 2 | $146 |
| Biohaven Pharmaceuticals, Inc. | 4 | $143 |
| Cvrx, Inc. | 1 | $131 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Currax Pharmaceuticals LLC | 3 | $55 |
| Exact Sciences | 3 | $54 |
| AbbVie(2 entities) | 3 | $52 |
| Sanofi Pasteur Inc. | 1 | $52 |
| Arthrex | 1 | $45 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Corcept Therapeutics | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$805
- FARXIGA$709
- JARDIANCE$688
- EVENITY$592
- Ozempic$345
- WATCHMAN FLX$250
- INVOKANA$246
- Repatha$244
- AREXVY$235
- Vascepa$227
- Barostim Neo System$131
- UPTRAVI$125
- OPSUMIT$125
- MitraClip System$125
- Wegovy$125
- BREZTRI$120
- ELIQUIS$117
- AIMOVIG$112
- STEGLATRO$112
- NURTEC ODT$112
How this compares
$10,624 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $72,129 |
| EliquisApixaban | 26 | $29,201 |
| JanuviaSitagliptin Phosphate | 36 | $27,973 |
| OzempicSemaglutide | 21 | $24,880 |
| MyrbetriqMirabegron | 17 | $12,277 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $10,660 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,080 |
| TrulicityDulaglutide | 11 | $10,059 |
| VascepaIcosapent Ethyl | 18 | $8,677 |
| SynthroidLevothyroxine Sodium | 55 | $5,517 |
| PremarinEstrogens, Conjugated | 11 | $5,357 |
| Levothyroxine Sodium | 384 | $3,152 |
| Losartan Potassium | 281 | $2,931 |
| Atorvastatin Calcium | 338 | $2,863 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $2,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,237 | $72,12960 claims |
| PfizerEliquis, Premarin | $376 | $34,55837 claims |
| MerckJanuvia | $189 | $27,97336 claims |
| Novo NordiskOzempic | $974 | $24,88021 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $591 | $23,14156 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $12,27717 claims |
| Lilly USA, LLCTrulicity | $455 | $10,05911 claims |
| AbbVieSynthroid | $52 | $5,51755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Naples
- Lazaro Diaz-NunezNaples$12.8M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.